Exelixis, Inc. $EXEL Shares Sold by Intech Investment Management LLC

Intech Investment Management LLC decreased its stake in shares of Exelixis, Inc. (NASDAQ:EXEL) by 51.4% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 292,114 shares of the biotechnology company’s stock after selling 308,697 shares during the period. Intech Investment Management LLC’s holdings in Exelixis were worth $12,803,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of EXEL. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its stake in Exelixis by 81.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 43,181 shares of the biotechnology company’s stock valued at $1,592,000 after buying an additional 19,407 shares during the period. Goldman Sachs Group Inc. increased its stake in Exelixis by 4.9% during the 1st quarter. Goldman Sachs Group Inc. now owns 1,466,779 shares of the biotechnology company’s stock valued at $54,153,000 after buying an additional 68,133 shares during the period. Focus Partners Wealth increased its stake in Exelixis by 83.4% during the 1st quarter. Focus Partners Wealth now owns 38,458 shares of the biotechnology company’s stock valued at $1,420,000 after buying an additional 17,483 shares during the period. Geneos Wealth Management Inc. increased its stake in Exelixis by 134.3% during the 1st quarter. Geneos Wealth Management Inc. now owns 1,647 shares of the biotechnology company’s stock valued at $61,000 after buying an additional 944 shares during the period. Finally, Sivia Capital Partners LLC increased its stake in Exelixis by 23.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 14,362 shares of the biotechnology company’s stock valued at $633,000 after buying an additional 2,764 shares during the period. Institutional investors and hedge funds own 85.27% of the company’s stock.

Key Exelixis News

Here are the key news stories impacting Exelixis this week:

• Positive Sentiment: Zacks Research raised several forward earnings estimates for Exelixis, including Q2 2026, Q3 2026, FY2026, FY2027, and FY2028, suggesting analysts see improving profitability ahead. Zacks Research estimate updates
• Positive Sentiment: Exelixis said management will host fireside chats at upcoming June investor conferences, which can support investor confidence by highlighting strategy, pipeline progress, and commercial execution. Investor conference webcast announcement
• Positive Sentiment: Wall Street commentary and fair-value updates have trended higher, with one article noting a refreshed fair value estimate near $49.65 and broader debate about Exelixis’s growth and competitive position. Fair value target article
• Neutral Sentiment: Shareholders approved the company’s equity plan and board slate at the annual meeting, a routine governance update that removes an overhang but is not a major catalyst on its own. Shareholder approval article
• Neutral Sentiment: Executive Vice President Dana Aftab sold 43,451 shares for about $2.19 million. Insider sales can weigh on sentiment, but this does not necessarily signal a change in the company’s fundamentals. Insider sale filing
• Negative Sentiment: One Zacks note trimmed Q1 2027 EPS estimates slightly and maintained only a Hold rating, showing that not all analysts are turning more bullish. Zacks Hold rating and estimate cut

Exelixis Stock Performance

EXEL stock opened at $50.48 on Friday. The stock has a market cap of $12.69 billion, a P/E ratio of 16.77, a P/E/G ratio of 1.08 and a beta of 0.38. The firm has a 50 day simple moving average of $46.01 and a 200 day simple moving average of $44.22. Exelixis, Inc. has a 52 week low of $33.76 and a 52 week high of $52.96.

Exelixis (NASDAQ:EXEL) last posted its quarterly earnings results on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.75 by $0.12. The business had revenue of $610.81 million during the quarter, compared to analysts’ expectations of $607.51 million. Exelixis had a net margin of 35.08% and a return on equity of 39.89%. The firm’s quarterly revenue was up 10.0% compared to the same quarter last year. During the same period last year, the company posted $0.55 earnings per share. Sell-side analysts predict that Exelixis, Inc. will post 3.18 EPS for the current year.

Insider Transactions at Exelixis

In other news, SVP Brenda Hefti sold 6,625 shares of the business’s stock in a transaction on Monday, May 18th. The shares were sold at an average price of $50.21, for a total value of $332,641.25. Following the completion of the sale, the senior vice president directly owned 106,762 shares in the company, valued at approximately $5,360,520.02. The trade was a 5.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Patrick J. Haley sold 32,110 shares of the business’s stock in a transaction on Wednesday, May 20th. The stock was sold at an average price of $49.81, for a total transaction of $1,599,399.10. Following the completion of the sale, the executive vice president owned 357,638 shares of the company’s stock, valued at $17,813,948.78. The trade was a 8.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 205,433 shares of company stock valued at $9,930,259. Insiders own 2.60% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on EXEL shares. HC Wainwright lifted their price objective on shares of Exelixis from $54.00 to $56.00 and gave the stock a “buy” rating in a research note on Thursday, May 7th. Barclays lifted their price objective on shares of Exelixis from $44.00 to $45.00 and gave the stock an “equal weight” rating in a research note on Monday, April 20th. Weiss Ratings reaffirmed a “buy (b)” rating on shares of Exelixis in a research note on Tuesday, May 19th. Truist Financial raised shares of Exelixis to a “strong-buy” rating in a research note on Monday, April 27th. Finally, Stifel Nicolaus lifted their price objective on shares of Exelixis from $44.00 to $47.00 and gave the stock a “hold” rating in a research note on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, eleven have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and a consensus target price of $47.35.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.